Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Rel... ( NASHVILLE Tenn. span class xn-ch...)

Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort

Date:1/20/2010

NASHVILLE, Tenn., Jan. 20 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. ( CPIX) has donated 15,000 vials of Caldolor® (ibuprofen) Injection, an intravenous form of ibuprofen, to Haitian relief effort.

Caldolor is the first and only injectable product approved for the treatment of pain and reduction of fever in the United States. As health conditions in Haiti continue to deteriorate, Caldolor is expected to help those suffering from fever as a result of disease or infection as well as patients suffering with pain from traumatic injury or while recovering from surgery. Cumberland provided the drug through a U.S.-based medical unit that will support field medical personnel in Haiti, including the international aid group Doctors Without Borders.

"As we learn more about the devastation this quake has caused as well as the conditions aid workers are facing, it is incumbent upon us to do what we can to ease this suffering," said A.J. Kazimi, Cumberland's Chief Executive Officer. "We are hopeful the donation of Caldolor will be especially relevant in light of mounting public health concerns about the outbreak of disease and the lack of adequate medical facilities and supplies."

Survivors and aid workers are facing dire health conditions, including stifling heat and raw sewage as well as lack of access to food, water or medical treatment. Health experts have warned that thousands of people could die as a result of infectious disease or infection from improperly treated wounds.

Caldolor was approved by the FDA and introduced in the United States in 2009. Clinical trials have sh
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
2. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
10. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
11. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac

Post Your Comments:

(Date:5/17/2013)... , May 17, 2013 Sony Biotechnology Inc. ("Sony") ... 8-well strip holder and 130um sorting chip. Sony will also ... on its new SH800 Cell Sorter, the EC800 flow cytometer, ... tutorials at CYTO 2013, which will be held at the ... San Diego, California , from May 20 - ...

(Date:5/17/2013)... 17, 2013 TechAtlas Group has announced the ... landscape map for the Chronic Kidney Disease (CKD) ... companies with drugs and devices currently on the ... sequelae. (Logo: http://photos.prnewswire.com/prnh/20130517/NE16011LOGO ... hypertension - renal denervation , diabetic nephropathy ...

(Date:5/17/2013)... Fuse Science, Inc. (OTCQB: DROP), ( www.fusescience.com ) ... new, patent-pending technologies poised to redefine how consumers receive energy, ... a business update teleconference and webcast for shareholders and the ... 4:30 PM ET. Fuse Science, Inc. CEO, ... and will be joined by Rubin Hanan ...

Breaking Medicine Technology:Sony Delivers New Technology for Science to CYTO 2013 2 TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map 2 Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd 2

[0] Sony Delivers New Technology for Science to CYTO 2013 [0] TechAtlas Group Releases Innovative Chronic Kidney Disease Landscape Map [0] Fuse Science, Inc. to Hold Business Update Webcast and Teleconference on May 22nd

... AMSTERDAM, September 19, 2011 Agendia, ... that a published report highlighting the development and ... was published online in Breast Cancer Research ... a part of Agendia,s Symphony™ suite of breast ...

... Laser Med Center , which specializes in treating Trigeminal ... laser device. This is a non-invasive alternative to surgery, ... Trigeminal Neuralgia is a terribly painful condition of ... (the fifth cranial nerve or CN5) is primarily a ...

Cached Medicine Technology:Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 2 Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint® 3 FDA Approved, Non-Invasive Laser Is A Success in Trigeminal Neuralgia Pain Treatment 2

Breast Cancer Research and Treatment Highlights Development and Validation of BluePrint®FDA Approved, Non-Invasive Laser Is A Success in Trigeminal Neuralgia Pain Treatment

(Date:5/18/2013)... American Gastroenterological Association (AGA) Research Foundation is pleased ... honorees are outstanding young gastroenterologists working toward independent ... with this award, their research time will be ... future of our field. AGA is committed to ... for promising research developments and new therapies," said ...

(Date:5/18/2013)... By Dennis Thompson HealthDay Reporter , , FRIDAY, ... Association unveils the latest edition of what is considered ... over its many changes continues. "This is unprecedented, ... Dr. Jeffrey Lieberman, president-elect of the American Psychiatric Association ... is what it is. You have to evaluate it ...

(Date:5/18/2013)... The use of a smartphone application significantly ... new research presented today at Digestive Disease Week ... advance of the procedure, includes dietary restrictions and ... at strict intervals. The better the preparation, the ... and precancerous polyps in the colon. The study, ...

(Date:5/18/2013)... 2013 Assisted living and retirement ... safety and comfort of their residents. Systems Technologies ... with an effective and cost-efficient solution – VisionLink ... integrated, turnkey communications solution that helps nurses provide ... independence and privacy. , The VisionLink ...

(Date:5/18/2013)... The Communities of Distinction TV program presents ... These are the townships, villages and other small spots not ... people are friendly and neighbors are there when you need ... shares the best in both the United States and Canada. ... and film celebrity. It airs in May and will run ...

Breaking Medicine News(10 mins):Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2 Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2 Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3 Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4 Health News:New smartphone application improves colonoscopy preparation 2 Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 2 Health News:VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities 3 Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2

[0] AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists [0] Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy [0] New smartphone application improves colonoscopy preparation [0] VisionLink Nurse Call System's New Features Serve the Unique Needs of Retirement Communities [0] Communities of Distinction TV Presents "A Place to Call Home" Segment

... a catastrophic epidemic of smoking deaths, which is expected to cause ... including one in five of all male deaths and one ... male bidi smokers lose about six years of life, female bidi ... ten years. , The findings are from the first nationally ...

... ReBuilder Medical,Technologies, Inc. (Pink Sheets: RBRM), ... for diabetic peripheral neuropathy, Molluscum,Contagiosum, and MRSA, ... year, details,are available on their Annual Report ... http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO ), "The company,s growth ...

... German trial could be a breakthrough treatment in vascular ... stents haven,t worked well for blocked leg arteries, but ... balloons, which are inserted at the end of catheters ... whose balloons were coated with paclitaxel, one of the ...

... Approves Stock Repurchase Program, Raising 2008 EPS Guidance to $2.58 to $2.73 ... ... BEACH, Va., Feb. 13 AMERIGROUP,Corporation (NYSE: AGP ) today announced ... $31.1 million, or $0.57 per diluted,share, versus net income of $29.9 million, ...

... Feb. 13 Watson,Pharmaceuticals, Inc. (NYSE: WPI ... the U.S. Food and Drug Administration ("FDA"),has initiated ... regarding the duration or outcome of the inspection ... Florida manufacturing facility has,been under Official Action Indicated ...

... trauma disorder as good a marker for health status as ... People with post-traumatic stress disorder (PTSD) are as likely to ... disease risk factors, a new study suggests. , The findings, ... of Nervous and Mental Disease , come from examining the ...

India caught in catastrophic smoking epidemic ReBuilder Medical Technologies, Inc. Announces 2007 Sales Nearly Doubled Sales in 2006 Drug-Coated Balloons Keep Leg Arteries Open: Study AMERIGROUP Reports Q4 Net Income of $31.1 Million or $0.57 Per Diluted Share; Full-Year Net Income of $116.5 Million or $2.16 Per Diluted Share Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities PTSD a Risk Factor for Long-Term Disease

... temporary internal drainage from the ureteropelvic junction ... stricture. The segment with no sideports prevents ... preventing ingrowth of the ureteral wall to ... Intended for one-time use. CAUTION: Periodic evaluation ...

... for temporary internal drainage from the ureteropelvic ... a stricture. The segment with no sideports ... while preventing ingrowth of the ureteral wall ... packages. Intended for one-time use. CAUTION: Periodic ...

ACMI™ 4.8 Fr Closed Tip Ureteral Stents are easily inserted through the 5 Fr working port of an endoscope. Large internal lumens enhance urinary flow, promoting the kind of drainage you might o...

... Used for retrograde ... and subsequent ureteral stent ... has a radiopaque band ... to aid in fluoroscopic ...

Medicine Products:

ULTRATHANE Endoureterotomy Stent Sets C-FLEX Endoureterotomy Stent Sets 4.8 Fr Closed Tip Ureteral Stents Desilets-Hoffman Introducer Sets